Evidence map›Paper›PMID 39494251›Full record

ArticleAdvanced pharmaceutical bulletin2024

Unlocking Therapeutic Potential: Enhanced shRNA Delivery with Tat Peptide in the Human Respiratory Syncytial Virus Treatment.

Saeid Amiri Zadeh Fard, Haniyeh Abuei, Abbas Behzad Behbahani, Gholamreza Rafiei Dehbidi, Farahnaz Zare, Maryam Nejabat, Alireza Safarpour, Ali Farhadi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced pharmaceutical bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saeid Amiri Zadeh FardDiagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0003-2347-5204
Haniyeh AbueiDivision of Medical Biotechnology, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-2044-0666
Abbas Behzad BehbahaniDiagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0001-5917-920X
Gholamreza Rafiei DehbidiDiagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-5905-2222
Farahnaz ZareDiagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-3746-4621
Maryam NejabatShiraz HIV/AIDS research center, Institute of health, Shiraz University of medical sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-6818-2563
Alireza SafarpourGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-9880-0043
Ali FarhadiDiagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-2271-670X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This research investigated the development of short hairpin RNA (shRNA) molecules designed to target specific regions of the human respiratory syncytial virus (HRSV) M and F genes. The study aimed to assess the therapeutic potential of these shRNAs and evaluate the effectiveness of Tat peptide-mediated delivery in enhancing their functionality. Methods: We acquired isolates from pediatric patients experiencing respiratory illness then cultured in HEp-2 cells. We constructed plasmids expressing shRNAs. Tat peptide as a facilitator for shRNA plasmid delivery was used. The cytotoxicity of ribavirin, shRNA constructs, and control agents was assessed using the MTT assay. The transfection efficiency of Tat peptide-mediated shRNA delivery with that of lipofectamine 3000 Results: Tat peptide-mediated delivery of shRNA plasmids significantly suppressed the expression of the M and F genes of HRSV compared to lipofectamine 3000 Conclusion: Our findings suggest that Tat peptide-mediated delivery of shRNA plasmids holds significant potential for achieving stable suppression of HRSV genes. This approach warrants further investigation as a potential gene therapy strategy for HRSV. By demonstrating promising results in vitro, this study highlights the need for future in vivo studies to comprehensively evaluate the therapeutic potential of this approach in a clinical setting.

Indexed as

Fusion geneHuman respiratory syncytial virusMatrix geneReal-time PCRRibavirinshRNATat peptide

Identifiers

PMID39494251
PMCPMC11530872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.